T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the primary sequences of these drugs are the key dri...

Descripción completa

Detalles Bibliográficos
Autores principales: Jawa, Vibha, Terry, Frances, Gokemeijer, Jochem, Mitra-Kaushik, Shibani, Roberts, Brian J., Tourdot, Sophie, De Groot, Anne S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338774/
https://www.ncbi.nlm.nih.gov/pubmed/32695107
http://dx.doi.org/10.3389/fimmu.2020.01301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338774/
https://www.ncbi.nlm.nih.gov/pubmed/32695107
http://dx.doi.org/10.3389/fimmu.2020.01301

Ejemplares similares